Royalty Pharma plc (RPRX) has a MoatMap StockRank of 89/100 based on Quality (57/100), Value (31/100), and Momentum (85/100) factor scores. The current signal is STRONG BUY. Royalty Pharma is the ultimate asset-light compounder in the healthcare space, perfectly matching the Terry Smith and Warren Buffett lenses. By funding late-stage clinical trials and purchasing royalties on blockbuster therapies, RPRX avoids binary scientific risk while capturing high-margin, long-duration cash flows. In a macro environment where biotech funding is constrained and CDMO/manufacturing costs are rising, RPRX acts as an indispensable, non-dilutive capital provider, allowing it to secure highly favorable royalty terms.
Royalty Pharma plc is a unique healthcare company focused on acquiring royalty interests in marketed and late-stage biopharmaceutical products. The company's competitive moat lies in its specialized business model, offering capital to biopharmaceutical companies in exchange for future royalty payments, thereby de-risking investments in drug development. This strategy provides diversified exposure to blockbuster therapies without direct R&D costs.
| Price | $54.97 |
| Market Cap | $31.4B |
| P/E (TTM) | 28.96 |
| P/E (Forward) | 9.80 |
| Price/Book | 3.54 |
| Return on Equity | 13.8% |
| Return on Invested Capital | 8.6% |
| Debt/Equity | 90.32 |
| Gross Margin | 115.0% |
| Operating Margin | 100.3% |
| Revenue Growth | 11.0% |
| Dividend Yield | 1.7% |
| Free Cash Flow | $-980M |
Royalty Pharma plc operates in the Biotechnology industry, part of the Healthcare sector (United States).